卵巢高级别浆液性癌组织中p-ERK5、WT-1的表达及与临床病理特征的关系  

Expression of p-ERK5 and WT-1 in high-grade serous ovarian cancer and their relationships with clinicopathological features

作　　者：王艳敏 郭艳娟 刘聪慧 陈燕 WANG Yanmin;GUO Yanjuan;LIU Conghui;CHEN Yan(North China University of Technology Affiliated Hospital,Hebei Tangshan 063000,China;Luanzhou People's Hospital,Hebei Luanzhou 063700,China.)

机构地区：[1]华北理工大学附属医院,河北唐山063000 [2]滦州市人民医院,河北滦州063700

出　　处：《现代肿瘤医学》2024年第14期2596-2600,共5页Journal of Modern Oncology

基　　金：河北省医学科学研究课题计划项目(编号:20231260)。

摘　　要：目的:通过检测患者卵巢良恶性肿瘤组织中p-ERK5、WT-1蛋白的表达水平,分析二者在卵巢癌组织中是否高表达;通过分析p-ERK5、WT-1蛋白与卵巢高级别浆液性癌(high-grade serous ovarian cancer, HSOC)患者临床病理特征的关系,为HSOC的诊治提供新思路。方法:以2008年01月至2019年12月在华北理工大学附属医院妇科就诊的卵巢肿瘤患者为研究对象。根据患者首次病理诊断结果选择研究对象。本研究分为两部分,第一部分选择其中54例HSOC患者为病例组,50例卵巢浆液性囊腺瘤患者为对照组。收集患者卵巢肿瘤组织蜡块与临床病理资料,运用免疫组织化学法检测卵巢肿瘤组织中p-ERK5及WT-1蛋白的表达水平。第二部分选择54例HSOC患者,分别以p-ERK5及WT-1蛋白表达情况进行分组,分别分为低表达组及高表达组。采用独立样本t检验、χ^(2)检验比较p-ERK5及WT-1蛋白在卵巢良恶性肿瘤组织中的表达差异,采用χ^(2)检验、Fisher精确概率法、非参数Mann-whitney U检验及多因素Logistic回归分析二者的表达水平与HSOC患者临床病理特征的关系。结果:HSOC患者中p-ERK5及WT-1蛋白的高表达率均高于卵巢浆液性囊腺瘤组,两组比较差异有统计学意义(P<0.05)。单因素分析显示,p-ERK5及WT-1的表达与患者的临床分期、淋巴转移及3年内是否发生复发有关,其中临床分期高、有淋巴转移及3年内发生复发患者的p-ERK5及WT-1高表达率明显升高;合并腹水患者中p-ERK5的高表达率明显增高;p-ERK5及WT-1高表达患者的首诊CA125水平显著高于低表达的患者;差异均有统计学意义(P<0.05)。多因素Logistic回归分析显示,p-ERK5及WT-1高表达分别是发生淋巴转移和初治3年内发生复发的危险因素。结论:p-ERK5及WT-1蛋白高表达与HSOC患者的临床病理特征有关,患者更易发生淋巴转移及初治3年内发生复发。Objective:To detect the expression levels of p-ERK5 and WT-1 proteins in ovarian benign and malignant tumor tissues,and the relationship between the expression levels of p-ERK5 and WT-1 proteins in ovarian cancer was analyzed.The relationships between p-ERK5,WT-1 protein and clinicopathological features of high-grade serous ovarian cancer were analyzed to provide new ideas for the diagnosis and treatment of ovarian cancer.Methods:Patients with ovarian tumor were selected from the Department of Gynecology,Affiliated Hospital of North China University of Technology from January 2008 to December 2019.The subjects were selected according to the first pathological diagnosis.This study is divided into two parts.In the first part,54 HSOC patients were selected as case group,50 ovarian serous cystadenoma patients as control group.The clinical and pathological data of ovarian tumor were collected.The expression levels of p-ERK5 and WT-1 protein in ovarian tumors were detected by immunohistochemistry.In the second part,54 HSOC patients were selected.According to the expression of p-ERK5 and WT-1 protein,they were divided into low expression group and high expression group.The expression of p-ERK5 and WT -1 protein in benign and malignant ovarian tumors were compared by t test and χ 2 test.χ 2 test,Fisher's exact probability method,non-parametric Mann-whitney U test and multivariate Logistic regression were used to analyze the relationship between their expression levels and clinicopathological characteristics of high-grade serous ovarian cancer. Results: The high expression of p-ERK5 and WT-1 protein in case group were significantly higher than those in control group ( P <0.05).The expression of p-ERK5 and WT-1 was associated with clinical stage,lymph node metastasis and recurrence within 3 years in univariate analysis.The high expression rates of p-ERK5 and WT-1 were significantly increased in patients with high clinical stage,lymph node metastasis and recurrence within 3 years.The high expression rate of p-ERK5 was sig

关 键 词：卵巢高级别浆液性癌 p-ERK5 WT-1 免疫组织化学 临床病理特征 

分 类 号：R737.31[医药卫生—肿瘤]